研究者詳細 - 藤井　伸治

論文 - 藤井　伸治

分割表示 165 件中 161 - 165 件目／全件表示 >>

Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma 査読

Teruhiko Kozuka, Katsuyuki Kiura, Hideki Katayama, Nobuharu Fujii, Fumihiko Ishimaru, Kazuma Ikeda, Hiroshi Ueoka, Shuuji Hamasaki, Tadashi Yoshino, Yoshio Kashihara, Hiroshi Date, Mitsune Tanimoto, Mine Harada

Anticancer Research 22 ( 5 ) 2939 - 2944 2002年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

Background: Patients with recurrent soft tissue sarcoma (STS) are seldom curable, with 5-year survival rates of less than 10% in all large series. The role of high-dose chemotherapy (HDC) with hematopoietic stem cell support in this disease has not been established. Case Report: We report on two patients with recurrent STS who were treated with tandem HDC supported by autologous peripheral blood stem cell transplantation (PBSCT). One patient with malignant fibrous histiocytoma recurred with multiple lung metastases. This patient achieved a partial response after two cycles of induction chemotherapy consisting of ifosfamide and epirubicin. During four cycles of induction chemotherapy, peripheral blood stem cells (PBSCs) were harvested. Tandem high-dose ICE regimen (ifosfamide 3 g/m2 on days - 7 to - 3, carboplatin 400 mg/m2 on days - 7, - 5 and 3, etoposide 500 mg/m2 on days - 7, - 5 and 3) supported by autologous PBSCT gave rise to further regression of the tumors. Another patient with malignant hemangiopericytoma was treated by tandem high-dose ICE regimen supported by autologous PBSCT after the 3rd removal of abdominal tumors. Relapse-free intervals until the 1st, 2nd and 3rd relapses were 40, 19 and 22 months, respectively. Tandem high-dose ICE regimen might delay the relapse. Conclusion: These observations suggest that a tandem high-dose ICE regimen with autologous PBSCT is feasible with some clinical efficacy in the control of refractory STS.

Scopus

PubMed

researchmap

固形腫瘍におけるマイナー組織適合性抗原HA-1の発現の検討

平木章夫, 藤井伸治, 池田和眞, 木浦勝行, 田端雅弘, 上岡博, 原田実根, 谷本光音

日本癌学会総会記事 60回 243 - 243 2001年9月

Genetics of Epstein-Barr virus infection

A. Hiraki, N. Fujii, K. Masuda, K. Ikeda, M. Tanimoto

Biomedicine and Pharmacotherapy 55 ( 7 ) 369 - 372 2001年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Elsevier Masson SAS

Epstein-Barr (EBV) virus is a member of the human herpesvirus family. EBV is the etiologic agent of acute infectious mononucleosis and is closely associated with the genesis of Burkitt's lymphoma and undifferentiated nasopharyngeal carcinoma. EBV is also implicated in a variety of other diseases, such as X-linked lymphoproliferative syndrome, T-cell non-Hodgkin's lymphoma, Hodgkin's disease, and NK-cell granular lymphoproliferative disorder. Recently, lymphoepithelial carcinoma of the stomach, gastric carcinoma, pyothorax-associated lymphoma, and smooth muscle tumors were also recognized as EBV-associated diseases. It is therefore important to review the genetics and immunological response of EBV infection. In this review we summarize the genetics of EBV, immunological responses and clinical findings of EBV-associated diseases, which would help us to understand the pathophysiology of EBV-associated disease and develop specific treatments. © 2001 Éditions scientifiques et médicales Elsevier SAS.

DOI： 10.1016/S0753-3322(01)00084-1

平松靖史, 角南一貴, 前田嘉信, 藤井伸治, 別所昭宏, 浅野尚美, 小郷博昭, 竹中克斗, 品川克至, 池田和真, 原田実根

日本輸血学会雑誌 46 ( 1 ) 1 - 6 2000年

記述言語：日本語出版者・発行元：The Japan Society of Transfusion Medicine and Cell Therapy

Autologous blood stem cell transplantation (auto-PBSCT) has increasingly been incorporated into the treatment of various malignancies. Auto- PBSCT provides several advantages over auto-BMT, but sometimes requires several collections of PBSC. We have retrospectively analyzed the time requirements and cost effectiveness of PBSC collection in Okayama University Hospital between 1994 and 1997, in which PBSCs were mobilized by chemotherapy and granulocyte colony-stimulating factor in 85 patients. During the 1994-1995 period, PBSCs were collected by apheresis, which was timed by leukocyte count and carried out by attending physicians, and cryopreserved at<5×10⁷cells/ml concentrations. During 1996-1997, PBSC harvests, in which the number of apheresis was adjusted by the number of CD34⁺ cells collected at each harvest, were predicted by circulating immature myeloid cell count, and carried out by personnel of the Division of Blood Transfusion. Collected cells were cryopreserved at<1×10⁸cells/ml. From the 1994-1995 to 1996-1997 periods, the average number of apheresis, the number of cryopreserved bags, and the time and cost required for aphereses and cryopreservation decreased from 3.5 to 1.4 aphereses, from 12.1 to 4.5 bags, from 13.6 to 7.1 hours and from 317 to 113 thousand yen per patient, respectively. Our experience suggests that the time requirements and cost effectiveness of PBSC harvest may be improved with precisely timed apheresis by skilled personnel and with appropriately defined cryopreservation.

DOI： 10.3925/jjtc1958.46.1

CiNii Article

researchmap

492 ヒト末梢血幹細胞培養好塩基球におけるsuperoxide産生能の検討

濱田昇, 谷本安, 高尾和志, 藤井誠, 藤井伸治, 金廣有彦, 原田実根, 池田和真, 片岡幹男, 今城健二, 高橋清

アレルギー 49 ( 9 ) 1015 - 1015 2000年

　前のページ - 次のページ　

<藤井 伸治>

論文 - 藤井 伸治

<藤井　伸治>

論文 - 藤井　伸治